Evaluation of voriconazole pharmacodynamics using time-kill methodology
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsActivities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effectAntifungal pharmacodynamics: review of the literature and clinical applications.Evaluation of differential gene expression in fluconazole-susceptible and -resistant isolates of Candida albicans by cDNA microarray analysis.Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo.Review of the safety and efficacy of voriconazole.Antifungal amphiphilic aminoglycoside K20: bioactivities and mechanism of action.Saccharomyces cerevisiae biofilm tolerance towards systemic antifungals depends on growth phaseGenome-wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates.In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisClinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Amphiphilic Tobramycin Analogues as Antibacterial and Antifungal Agents.Successful salvage therapy of Fusarium endophthalmitis secondary to keratitis: an interventional case seriesCombination treatment of invasive fungal infections.Treatment with intrastromal and intracameral voriconazole in 2 eyes with Lasiodiplodia theobromae keratitis: case reports.A combination approach to treating fungal infections.Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Invasive fungal infections in the ICU.In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.Influence of voriconazole and fluconazole on reconstituted multilayered oesophageal epithelium infected by Candida albicans.SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies.Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.Comparison of voriconazole concentration in the aqueous humor and vitreous between non-scraped and scraped corneal epithelium groups after topical 1% voriconazole application.Antifungal pharmacodynamic characteristics of amphotericin B against Trichosporon asahii, using time-kill methodology.Influence of voriconazole and fluconazole on Candida albicans in long-time continuous flow culture.Differential Effects of Linkers on the Activity of Amphiphilic Tobramycin Antifungals
P2860
Q27025299-BA16ED2F-1417-4CB9-BE5C-4BDA4CCAAF61Q30452998-DFEBC579-8E4C-4C64-A137-B6FD5569D1D5Q33980861-420B0FEE-3CED-4BD4-882D-4D4D648BA640Q34083129-C2582ED6-6FB6-4764-99E6-40D65DCC40D2Q34142347-41623CB8-8041-401E-BEB3-15F95E241396Q34335230-2E94F5FC-7777-4649-A4FB-8B31A0231F56Q34544679-25E364C2-5048-444B-BF37-C7FAD507C2FFQ34637793-9BC40FEC-394D-49A9-A353-63E94F08F1FBQ34643153-43200729-B5AD-44D0-A3EF-5A869A597E81Q34887876-F2A69921-C2F4-46FD-81E8-63C0B86C38FAQ35005817-42D842DF-318D-4131-B96C-5798814A6D32Q35026481-C03A3221-0B28-4B89-A75B-0F21878D090AQ35745822-FC3E38DF-AA53-415E-9997-7FC65141CD32Q35859918-4E25B4FC-3952-49A3-A393-0A5386F34DCDQ35997511-CE6EE6E4-67E8-411E-B070-D36A3451078BQ36011378-1C7EACE3-B8EF-4823-B954-85AE2BEB4E11Q36152402-108A7061-170F-40F4-AA58-6A1C739F433DQ36305684-61F9DD59-050E-4327-829F-1E1A52163E9CQ37263435-AC5052CB-F4C4-4C53-9A12-8B46BED60421Q37608276-2EB966BB-CCBF-4064-86D9-ED5E92B311F8Q37643057-C04E6A35-8A98-4E61-BFC8-EE78132D0E49Q39133635-8CB4FBBC-01C1-4445-A240-9B4BEADCD854Q40525637-1F62984A-C5E1-402A-8A95-3DB121094F49Q42319613-D4CDF95F-AFA6-44F1-B3CD-BDF99849020BQ42432990-CF10EE35-74D4-4274-A60F-3B3A8DC55410Q42992175-E87C2E5A-B5FD-41F1-A009-03E3C90C4C7FQ43951545-C6856EEF-2324-4DAB-B031-F6FE0F4301B3Q44034268-DAB7CF9C-6246-4FC7-892B-8456F82996BCQ57814953-25B16227-EE22-4DF9-9F1A-CCC7DD75063E
P2860
Evaluation of voriconazole pharmacodynamics using time-kill methodology
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@ast
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@en
type
label
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@ast
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@en
prefLabel
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@ast
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@en
P2093
P2860
P1476
Evaluation of voriconazole pharmacodynamics using time-kill methodology
@en
P2093
P2860
P304
P356
10.1128/AAC.44.7.1917-1920.2000
P407
P577
2000-07-01T00:00:00Z